Who is Not a Good Candidate for MRSA Prodrug TXA709?

Daniel Pilch, PhD, explains which patients would not make good candidates for MRSA prodrug TXA709.

Daniel Pilch, PhD, associate professor, Rutgers Robert Wood Johnson Medical School, explains which patients would not make good candidates for MRSA prodrug TXA709. Dr. Pilch shares that TXA709 is capable of treating life-threatening bloodstream infections as well as skin and soft tissue infections. MRSA is also known for infecting bone; although distribution studies suggest that the drug can treat bone infections, more research still needs to be done.

Related Videos
View All
© 2023 MJH Life Sciences

All rights reserved.